NovoCure Ltd (NVCR) concluded trading on Wednesday at a closing price of $17.87, with 6.73 million shares of worth about $120.18 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 48.30% during that period and on October 16, 2024 the price saw a gain of about 0.51%. Currently the company’s common shares owned by public are about 107.08M shares, out of which, 97.51M shares are available for trading.
Stock saw a price change of 21.90% in past 5 days and over the past one month there was a price change of -0.83%. Year-to-date (YTD), NVCR shares are showing a performance of 19.69% which increased to 17.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $10.87 but also hit the highest price of $24.74 during that period. The average intraday trading volume for NovoCure Ltd shares is 1.02 million. The stock is currently trading 12.74% above its 20-day simple moving average (SMA20), while that difference is up 4.27% for SMA50 and it goes to 6.64% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NovoCure Ltd (NASDAQ: NVCR) currently have 107.08M outstanding shares and institutions hold larger chunk of about 85.77% of that.
The stock has a current market capitalization of $1.93B and its 3Y-monthly beta is at 0.70. It has posted earnings per share of -$1.57 in the same period. It has Quick Ratio of 6.22 while making debt-to-equity ratio of 1.87. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVCR, volatility over the week remained 12.00% while standing at 6.68% over the month.
Stock’s fiscal year EPS is expected to rise by 29.81% while it is estimated to decrease by -7.84% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on Oct-17-24 offering a Buy rating for the stock and assigned a target price range of between $24 and $30 to it. Coverage by JP Morgan stated NovoCure Ltd (NVCR) stock as a Neutral in their note to investors on November 20, 2023, suggesting a price target of $15 for the stock. On August 28, 2023, H.C. Wainwright Downgrade their recommendations, while on August 08, 2023, Piper Sandler Upgrade their ratings for the stock with a price target of $45. Stock get an Outperform rating from SVB Securities on August 04, 2023.
